Developmental expression of human hepatic CYP2C9 and CYP2C19

被引:227
作者
Koukouritaki, SB
Manro, JR
Marsh, SA
Stevens, JC
Rettie, AE
McCarver, DG
Hines, RN
机构
[1] Med Coll Wisconsin, Dept Pediat, Birth Defects Res Ctr, Milwaukee, WI 53226 USA
[2] Pfizer, Pharmacokinet Dynam & Metab, Kalamazoo, MI USA
[3] Univ Washington, Dept Med Chem, Seattle, WA 98195 USA
关键词
D O I
10.1124/jpet.103.060137
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The CYP2C subfamily is responsible for metabolizing many important drugs and accounts for about 20% of the cytochrome P450 in adult liver. To determine developmental expression patterns, liver microsomal CYP2C9 and -2C19 were measured (n = 237; ages, 8 weeks gestation-18 years) by Western blotting and with diclofenac or mephenytoin, respectively, as probe substrates. CYP2C9-specific content and catalytic activity were consistent with expression at 1 to 2% of mature values (i.e., specific content, 18.3 pmol/mg protein and n = 79; specific activity, 549.5 pmol/mg/min and n = 72) during the first trimester, with progressive increases during the second and third trimesters to levels approximately 30% of mature values. From birth to 5 months, CYP2C9 protein values varied 35-fold and were significantly higher than those observed during the late fetal period, with 51% of samples exhibiting values commensurate with mature levels. Less variable CYP2C9 protein and activity values were observed between 5 months and 18 years. CYP2C19 protein and catalytic activities that were 12 to 15% of mature values (i.e., specific content, 14.6 pmol/mg and n = 20; specific activity, 18.5 pmol/mg/min and n = 19) were observed as early as 8 weeks of gestation and were similar throughout the prenatal period. CYP2C19 expression did not change at birth, increased linearly over the first 5 postnatal months, and varied 21-fold from 5 months to 10 years. Adult CYP2C19 protein and activity values were observed in samples older than 10 years. The ontogeny of CYP2C9 and -2C19 were dissimilar among both fetal and 0- to 5-months postnatal samples, implying different developmental regulatory mechanisms.
引用
收藏
页码:965 / 974
页数:10
相关论文
共 35 条
[1]   IDENTIFICATION OF HUMAN LIVER CYTOCHROME-P450 ISOFORMS MEDIATING OMEPRAZOLE METABOLISM [J].
ANDERSSON, T ;
MINERS, JO ;
VERONESE, ME ;
TASSANEEYAKUL, W ;
TASSANEEYAKUL, W ;
MEYER, UA ;
BIRKETT, DJ .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 36 (06) :521-530
[2]   CYTOCHROME-P450 AND THE ARACHIDONATE CASCADE [J].
CAPDEVILA, JH ;
FALCK, JR ;
ESTABROOK, RW .
FASEB JOURNAL, 1992, 6 (02) :731-736
[3]   Liver-enriched transcription factors and hepatocyte differentiation [J].
Cereghini, S .
FASEB JOURNAL, 1996, 10 (02) :267-282
[4]   Identification of constitutive androstane receptor and glucocorticoid receptor binding sites in the CYP2C19 promoter [J].
Chen, YP ;
Ferguson, SS ;
Negishi, M ;
Goldstein, JA .
MOLECULAR PHARMACOLOGY, 2003, 64 (02) :316-324
[5]   Development of a comprehensive panel of antibodies against the major xenobiotic metabolising forms of cytochrome P450 in humans [J].
Edwards, RJ ;
Adams, DA ;
Watts, PS ;
Davies, DS ;
Boobis, AR .
BIOCHEMICAL PHARMACOLOGY, 1998, 56 (03) :377-387
[6]   Mechanism-based inactivation of cytochrome P4502B6 by a novel terminal acetylene inhibitor [J].
Fan, PW ;
Gu, CG ;
Marsh, SA ;
Stevens, JC .
DRUG METABOLISM AND DISPOSITION, 2003, 31 (01) :28-36
[7]   Regulation of human CYP2C9 by the constitutive androstane receptor:: Discovery of a new distal binding site [J].
Ferguson, SS ;
Lecluyse, EL ;
Negishi, M ;
Goldstein, JA .
MOLECULAR PHARMACOLOGY, 2002, 62 (03) :737-746
[8]   Transcriptional regulation of CYP2C9 gene -: Role of glucocorticoid receptor and constitutive androstane receptor [J].
Gerbal-Chaloin, S ;
Daujat, M ;
Pascussi, JM ;
Pichard-Garcia, L ;
Vilarem, MJ ;
Maurel, P .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (01) :209-217
[9]   Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine [J].
Giancarlo, GM ;
Venkatakrishnan, K ;
Granda, BW ;
von Moltke, LL ;
Greenblatt, DJ .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 57 (01) :31-36
[10]   Clinical relevance of genetic polymorphisms in the human CYP2C subfamily [J].
Goldstein, JA .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 52 (04) :349-355